Demographic and Clinical Characteristics of the Severe Covid-19 Infections: First Report from Mashhad University of Medical Sciences, Iran

Running title: Characteristics of Covid-19 in Iran

Ladan Goshayeshi[1,2], Mina Akbari Rad[3], Robert Bergquist[4], Abolghasem Allahyari[3], Kamila Hashemzadeh[5], Nasrin Milani[3], Mahdi Gholian-Aval[6], Fariba Rezaeitalab[7], Mohammad Jafar Sadeghi Quchani[8], Zahra Nahbandani[8], Zahra Javid[7], Mahnaz Mozdourian[7], Mohammad Ali Yaghoubi[9], Zahra Mozaheb[10], Mohsen Seddigh-Shamsi[10], Mohammad Moeini Nodeh[10], Shima Nabavi[3], Mandana Khodashahi[5], Hooman Mosannen Mozaffari[1], Mohammadreza Farzanehfar[1], Zahra Lotfi[3], Alireza Shariati[3], Shekoofe Bonakdaran[9], Zahra Rezaieyazdi[9], Zahra Mirfeizi[5], Maryam Miri[11], Reza Bassiri[7], Sajjad Ataei Azimi[10], Benyamin Hoseini[12,13,*]

[1]*Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*

[2]*Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.*

[3]*Department of internal medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*

[4]*Ingerod, SE-454 94 Brastad, Sweden.*

[5]*Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.*

[6]*Department of Health education & Health promotion, Social determinants of health research center, School of health, Mashhad University of Medical Sciences, Mashhad, Iran.*

[7]*Lung Disease Research Center, Mashhad University of Medical Sciences, Mashhad, Iran*

[8]*Department of health, Social determinants of health research center, Mashhad University of Medical Sciences, Mashhad, Iran.*

[9]*Metabolic syndrome research center, Mashhad University of Medical Sciences, Mashhad, Iran.*

[10]*Department of Hematology & Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*

[11]*Kidney transplantation complications research center, Mashhad University of Medical Sciences, Mashhad, Iran.*

[12]*Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.*

[13]*Department of Health Information Technology, Neyshabur University of Medical Sciences, Neyshabur, Iran.*

Ladan Goshayeshi and Mina Akbari Rad contributed equally as joint lead authors.

[*]***Corresponding author**:* **Benyamin Hoseini**, *Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Health Information Technology, Neyshabur University of Medical Sciences, Neyshabur, Iran; Tel: +985143306219, Cellphone: +989127858864; Email: Hoseinib1@nums.ac.ir.*

Abstract

Purpose. To report a comparison between fatalities and recovery of the severe Covid-19 infected patients based on demographic and clinical characteristics.

Methods. Between 5 March and 12 May 2020, of 4,000 patients, 1,278 were laboratory confirmed to be Covid-19 infection in Mashhad, Iran. Finally, 334 deceased and 733 recovered cases were assessed in terms of demography, exposure history, health outcomes and clinical symptoms.

Results. Mean (SD) age for confirmed patients, for deceased cases and for recovered cases. Mean±SD age for all confirmed-patients was 56.9±18.74, for the fatalities 67.26±15.77 and for those recovered 52.82±17.91 years. The rise of the mortality rate in relation to seniority was statistically significant. Despite a high frequency of Covid-19 infections accrued in the age groups of 30-39 and 40-49 years, most of these cases (88.2 and 85.8%, respectively) recovered. The median (IQR) duration of hospitalization was 9.0 (9) days. The most prevalent co-morbidities were cardiovascular disorders (21%) and diabetes (16.3%). Fever (63.8%), cough (68.1%), and dyspnoea (72.7%) were the most frequent clinical symptoms. 5.2% of infected-cases were healthcare workers that two (3%) of them died. Most patients (48%) received both antiviral and antibiotic therapy. The mortality rate of Kaletra combination prescribed for severe cases was 46.7%.

Conclusions. The characteristics of Covid-19 varied from died to survived infected patients. There were a higher number of fatalities in younger patients than in international studies. Diabetes and cardiovascular disorders were most prevalent co-morbidities. The study could not address the case-fatality rate of Covid-19 infection that remains for future studies.

Keywords. COVID-19; SARS-COV-2; Epidemiological characteristics; symptoms; mortality; Iran

Background

In late 2019, the city of Wuhan, Hubei Province, China became the centre of an unusual pneumonia-like disease of an unknown cause [1-4]. In December 2019, Chinese scientists realized that this condition was caused by a novel type of Coronavirus, first called 2019-nCOV [5, 6]. On January 7, 2020, scientists isolated this novel type of Coronavirus from the sputum of these patients, which was on February 11, 2020 classified as Severe Acute Respiratory Syndrome Coronavirus type two (SARS-CoV-2) by the International Committee on Taxonomy of Viruses [6, 7]. On the same date, the World Health Organization (WHO) named the disease caused by this virus coronavirus disease 2019 (Covid-19) in the International Classification of Diseases [6]. As of March 11, 2020 when the Covid-19 outbreak had spread worldwide and reached 118,319 confirmed cases and 4,292 confirmed deaths, WHO declared it a global pandemic [8-10]. The initial source of Covid-19 is still unknown, but it is now confirmed that the first known case of this disease was linked to the Huanan seafood market of Wuhan City, which was closed on January 1, 2020 to control the situation [4, 11].

SARS-CoV-2 is a member of the Coronaviridae family that consists of a single-stranded positive-sense RNA [4]. So far, two human infections by viruses related to Coronaviridae family are known: the Severe Acute Respiratory Syndrome (SARS), caused by SARS-CoV, which emerged in China in 2002 and spread across 37 countries, and the Middle-East Respiratory Syndrome (MERS), caused by MERS-CoV, which was first seen in Saudi Arabia in 2012 [4]. There were two separate outbreaks of SARS in the period 2002-2004, while cases of MERS still occur though only rarely [12]. SARS-COV-2 is genetically related to SARS-CoV with both of them being beta-coronaviruses [13, 14].

The clinical manifestation of Covid-19 varies from asymptomatic infection to severe viral pneumonia with multi-organ failures leading to death [3, 15]. The most common clinical manifestations include, but are not limited to, fever, non-productive cough, myalgia, fatigue and dyspnoea. Chest radiography shows bilateral lung infiltrations indicative of pneumonia and blood tests produce increased sedimentation rate C-Reactive Protein and lymphocytopenia [15, 16]. In severe cases, acute respiratory distress syndrome, acute damage to the heart and kidneys as well as shock can occur and with the patient suffering a series of irreversible organ injuries leading to death [16].

By May 16, 2020, there were 4,602,900 confirmed cases with 307,135 confirmed deaths globally, translating into a case fatality rate (CFR) of 6.67%. At this date, there were 116,635 confirmed cases with 6,902 deaths in Iran resulting in the same CFR (WHO daily report). Due to the rapid global spread of Covid-19, we estimate that an updated analysis of cases throughout one province of Iran, which consists of around 6.5 million population, might help to define more specifically define the clinical characteristics of Covid-19. Accordingly, we report here demographic and clinical characteristics of the severe Covid-19 patients comparing those deceased with those surviving in Mashhad, Iran.

Methods

A cross-sectional study of a local population-based cohort of patients consecutively fallen ill was conducted between 5 March and 12 May 2020 in Mashhad, Iran. Data came from the centre for Diseases Prevention and Control of Mashhad University of Medical Sciences. 94% of the cases were inpatients from hospitals affiliated to this University. Among 4,000 cases with severe symptoms, 1,278 cases were confirmed as true Covid-19 cases by real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of nasal and\or pharyngeal swabs. Clinical and demographic results from these 1,278 laboratory-confirmed cases were included in a review of exposure history, health outcomes and symptoms. Admission to an intensive care unit (ICU) or the use of mechanical ventilation within this cohort were the primary end-points. Secondary end-point was the duration of hospitalization that was defined as the time from onset of symptom(s) until discharge from the hospital as dead or recovered. The study could not calculate CFR of Covid-19 infection due to small sample size and selection bias. Fever was defined by axillary temperature of 37.5°C or higher. Prescribed medications were the Kaletra combination (ritonavir-boosted lopinavir used for treatment of HIV-1) and antibiotic which was prescribed for severe cases, and tamiflu (Oseltamivir phosphate - normally used for treatment of influenza) combination which was prescribed for mild cases.

Statistics analyses

Categorical variables were summarized as frequencies and percentages. Shapiro–Wilk tests were used to examine normality of data. Normally distributed data were expressed as mean ± standard deviation (SD), and skewed data as median and interquartile range (IQR). Two-tailed Student's t and Mann–Whitney U tests were used to compare grouped continuous variable data where appropriate. Chi-square and Fisher's exact tests were used to perform intergroup and categorical comparisons as appropriate. Reported *p*-values of <0.05 were considered statistically significant. SPSS software, version 16 (SPSS Inc., Chicago, IL, USA) was used to analyse the data and Google Sheets to depict Figure.

Results

Demographic characteristics. Of 1,278 laboratory-confirmed cases, 211 were still under treatment and the outcomes were unknown at the time of data cutoff on 12 May, so we were limited to 1,067 patients, out of whom 334 people had died and 733 recovered. Mean (SD) age for confirmed patients was 56.9 years (18.74), for deceased cases 67.26 years (15.77) and for recovered cases 52.82 years (17.91). There was a statistically significant association between age and mortality with the mortality rate rising with age. Despite the high frequency of Covid-19 infections accrued in the 30-39 and 40-49 age groups, most of them (105/119 = 88.2 and 133/155 = 85.8%, respectively) recovered (Table 1); it should be added that only 26/1,278 (2.03%) were younger than 20 years old and only 28/1,278 (2.2%) older than 89 (Fig. 1). Fatality among different age groups was depicted in Figure 2. Most the infected patients were males (793/1,278 = 62%). There was no statistically significant difference in outcomes with reference to gender (Table 1).

Table 1. Association between Covid-19 status and outcomes

Variable investigated		Outcome Number (%)		*P*-value
		Deceased (n = 334)	**Recovered** (n = 733)	
Continuous age - mean (SD)		67.26 (15.77)	52.82 (17.91)	0.0001
Age N=1,066	0-9	1 (9.1)	10 (90.9)	0.0001
	10-19	1 (11.1)	8 (88.9)	
	20-29	4 (7.5)	49 (92.5)	
	30-39	14 (11.8)	105 (88.2)	
	40-49	22 (14.2)	133 (85.8)	
	50-59	44 (21.9)	157 (78.1)	
	60-69	98 (41.7)	137 (58.3)	
	70-79	73 (47.7)	80 (52.3)	
	80-89	59 (54.1)	50 (45.9)	
	90-99	17 (81.0)	4 (19.0)	
	100-109	1 (100)	0 (0.0)	
Gender N = 1,067	Female	123 (30.4)	281 (69.6)	0.34
	Male	211 (31.8)	452 (68.2)	
Therapeutic approach N= 860	Antiviral & antibiotic	127 (30.2)	294 (69.8)	0.008
	Conservative	68 (40.0)	32 (60.0)	
	Antiviral	70 (26.0)	199 (74.0)	
Specific medication used N= 238	Kaletra combination and antibiotic[a]	21 (46.7%)	24 (53.3%)	
	Oseltamivir combination[b]	43 (22.3%)	150 (77.7%)	
Body temperature (Cº) - mean (SD) N = 648		37.7 (0.95)	37.74 (0.83)	0.38
Hospitalization (days) - median (IQR) N= 1,027		9 (10)	9 (9)	0.1

[a]prescribed for severe cases; [b]prescribed for mild cases.



Fig 1. The frequency of the severe Covid-19 infections in different age groups.



Fig. 2. Fatality rate among different age groups of the study area.

Patient end-points. Of the 1,278 patients with severe Covid-19 infection, the 125/1,058 (11.81%) cases were admitted to an ICU, and\or 231/834 (27.7%) cases underwent mechanical ventilation (Table 2). Of 125 cases admitted to an ICU and 231 cases used mechanical ventilation, 58 (46.4%) and 81 (35.06%) cases died, respectively. The median (IQR) duration of hospitalization was 9.0 (9) days and there was not statistically significant difference between duration of those who discharged and those who died (Table 1).

Co-morbidities and symptoms. The most frequent co-morbidities were cardiovascular disorders and diabetes consisting of 268/1,278 (21.0%) and 208/1,278 (16.3%) cases, respectively. Dyspnoea, cough, and fever were the most frequent clinical symptoms with 929 (72.7%), 870 (68.1%) and 815 (63.8%) cases, respectively. Compared with survivors, deceased cases showed a higher rate of co-morbidities including cardiovascular disorders (29.7% vs. 19.4%), diabetes (21.3% vs. 15.7%) and chronic respiratory disorders (7.8% vs. 3.6 %), respectively (Table 2).

Therapeutic approach. Most patients, i.e. 486/1,012 (48%) received both antiviral and antibiotic therapy, while 321/1,012 (31.7%) and 205/1,012 (20.3%) received antiviral and conservative therapies (without antiviral and antibiotic), respectively. There was no statistically significant association between therapeutic approach and mortality rate (Table 1). The mortality rate of the Oseltamivir combination prescribed for mild cases and the Kaletra combination prescribed for severe cases was 22.3% and 46.7%, respectively (Table 1).

Table 2. Frequency of co-morbidities and symptoms due to COVID-19 infections

Frequency / Co-morbidity	Frequency (%)		
	Among all infected cases (n= 1,278)	**Among deceased cases (n= 334)**	**Among recovered cases (n= 733)**
Cardiovascular disorder	268 (21.0)	97 (29.04)	142 (19.37)
Diabetes	208 (16.3)	71 (21.26)	117 (15.7)
Liver disorders	45 (3.5)	17 (5.09)	27 (3.68)
Kidney disorders	40 (3.1)	18 (5.39)	21 (2.86)
Chronic resp. disorder	57 (4.5)	26 (7.78)	26 (3.56)
Acute resp. distress syndrome (ARDS)	13 (1.02)	4 (1.2)	9 (1.23)
Mild pneumonia	136 (10.64)	17 (5.09)	93 (12.69)
Symptom			
Fever	815 (63.8)	205 (61.38)	492 (67.12)
Cough	870 (68.1)	201 (60.18)	536 (73.12)
Dyspnoea	929 (72.7)	266 (79.64)	513 (69.99)
General malaise	247 (19.3)	59 (17.66)	149 (20.33)
Myalgia	199 (15.6)	41 (12.27)	123 (16.78)
Confusion	87 (6.8)	34 (10.2)	38 (5.2)
Sore throat	152 (11.9)	27 (8.08)	98 (13.37)
Diarrhoea	47 (3.7)	9 (2.7)	31 (4.23)
Nausea & vomiting	113 (8.8)	22 (6.59)	76 (10.37)
Headache	114 (8.1)	17 (5.09)	68 (9.28)
End-points			
ICU admission	125/1,058 (11.8)	58/254 (22.8)	49/602 (8.14)
Using mechanical ventilation	231/834 (27.7)*	81/196 (41.33)*	118/482 (24.5)*
Other			
Exposure or visit to hospital within the last 14 days	106/867 (12.2)*	30/164 (18.3)*	65/447 (14.5)*
Contact with a respiratory patients in the last 14 days	78/823 (9.48)*	11/105 (10.5)*	43/334 (12.9)*

*indicating missing values

Out of the 1,278 patients, 67 (5.2%) cases (45 male and 22 female) were healthcare workers that 2 (3.0%) death. Among these 67 cases, 6 (8.9%) was admitted to an ICU and 7 (14.9%) cases underwent mechanical ventilation. With regard to symptoms 68.7% reported fever, 77.6% cough and 56.7% dyspnoea. Three had cardiovascular disorder and 3 diabetes; 31 had a history of contact with a Covid-19 patient.

Discussion

This is the first research in Mashhad, Iran to report the characteristics of the severe Covid-19 patients with their infections confirmed by RT-PCR. The study found that a rising age in this group of patients enhance the risk of mortality. The most frequent co-morbidities were diabetes and cardiovascular disorders and the most frequent symptoms dyspnoea, cough, and fever. In addition, the most frequent infections occurred in age groups of 50-59 and 60-69 years, while the highest rate of fatality was in the age group of 80-89 years. These findings are in line with other researchers' reported findings [6, 17].

According to our data, the mean (SD) age of Iranian Covid-19 patients is 56.9 (18.74) years, which is in agreement with other studies [16, 18, 19], but older than that reported by Guan et al. [20] who reported a median age (IQR) of 47.0 (35.0 - 58.0) years where 55.1% of their cases were between 15-49 years old (1) and also younger than the 64 years reported in other studies [21, 22]. Although, the most frequent Covid-19 infection occurred in the 50-59 and 60-69 age groups, the frequency of infection was also considerable in age groups of 30-39 and 40-49 years. The high frequency of Covid-19 infection in these age groups may be due to low median age (30 years) of the Iranian population and/or due to inclusion of mainly working-age population in this age group [23]. It seems that the frequency of Covid-19 infections rises considerably from age group of 50-59 years [24]. In contrast to findings in China and Italy [6, 25], we found a considerably higher proportion of fatalities in the age groups panning the range from 20 to 50 year of age.

Although our findings revealed statistically no significant association between gender and the outcome of Covid-19 infection, the prevalence of the Covid-19 infection was higher among Iranian men when compared with the reports of China. 62% of our cases were males while it only (49.3% - 54.3%) in China [16, 21]. However, our finding was in line with the reports of Italy (60%) [26], and the United States (63%) [22].

Huang et al.'s study [17] reported 15% CFR in China. However, they study only admitted hospital cases, leading to selection bias, as according to WHO daily report 5.6% CFR is reported in China by May 10, 2020. At the beginning of the Covid-19 outbreak in Italy, CFR was reported 11.8% (12,430/105,792) [27] for this country, but it is decreased as their sample size is increased. In our study, owing to resource restriction, RT-PCR testing was only used for cases with severe symptom at a high risk of mortality compared to other patients, leading to selection bias. Another limitation could be the inclusion of a comparatively low number of cases detected within a short time-horizon. Regarding these limitations and to avoid reporting misleading result, our study did not address calculating CFR that remains for future studies. A long-term screening of all population at risk in future should let us to report a more reliable CFR. The more important infection fatality rate (IFR) would also be of interest but would require a reliable antibody detection assay and a rather large human's sample, which would be beyond the aims of this study.

According to WHO interim clinical guidance (Rev. March 20, 2020) [28], fever, caught, fatigue and anorexia are the most common signs of Covid-19 and our findings comply. However, in the case of dyspnoea, our results (72.7%) were twice the prevalence suggested by WHO (31-40%) [28]. On the other hand, they were in line with other studies reported from United States [22, 29]. It is noteworthy that the prevalence of dyspnoea in the Chinese population complies with the WHO guidelines [18, 21, 30], while they can also be slightly higher [31]. It seems that the WHO should update the information based on new global data pointing out that there may be differences with respect to region.

Cardiovascular disorders (21%) and diabetes (16.3%) were the most prevalent co-morbidities among Covid-19 patients in our study. Previous studies have reported diverse prevalence rates ranging from 11% to 45% for cardiovascular disorders and from 13% to 35% for diabetes [18, 22, 29, 32]. A meta-analysis reports an overall pooled prevalence of 8.4% and 9.7% [33] for cardiovascular disorders and diabetes, respectively, while another meta-analysis reports 12% and close to 8% [34]. As soon as the pandemic started in Iran, the National Covid-19 Committee was set up and raised awareness of the risk, bringing forth the hypothesis that awareness of the infection risk may be associated with lower prevalence of co-morbidities. Assessing the association between patients' awareness and adherence to the prevention protocols remains for the future studies.
The fatality rate among healthcare workers was 3% in our study is considerably higher than that (0.33%) reported in China [35]. It might be due to shortage of protection equipment in the beginning of the Covid-19 pandemic in Iran. Future studies will confirm after fixing the shortage of protection equipment whether fatality has decreased among healthcare workers or not. The low number of health workers in our material (5.2%) could also have played a role.

While it was reported by Huang et al. that 32% of patients were admitted to ICU [36], we only transferred 11.8% of cases there. In addition, the fatality rate in the ICU in our study was 46.4%, which is lower than that (78%) reported by Zhou et al. [6]. All patients admitted to ICU received broad-spectrum antibiotics and antiviral medications, a combination that may have contributed to the lower mortality rate. Examination of this hypothesis remains for future studies. Another reason is that ICU care was carried out by an expert hospital team. Importantly, the use if the RT-PCR testing of all ICU-admitted patients strengthened the reliability of the fatality rate of this category of patients.

To our knowledge, this is the first study addressed the characteristics of Covid-19 patients confirmed by RT-PCR in Mashhad, Iran. However, RT-PCR testing was mostly only applied to cases with severe symptoms. This selection bias accompanied with too small sample size did not let us to calculate and report CFR in our study that remains for future studies. Because many patients were under treatment and the outcomes were unknown at cut-off date, we could not analyse their clinical outcomes at the analyses time. Owing to incomplete laboratory testing at the time, we could not analyse laboratory data which therefore remain for future studies. The data analysed here came from Mashhad University of Medical Sciences which do not cover all areas of Razavi Khorasan and this might have led to exclusion of cases from some region of the study area. Despite above-mentioned limitation, we feel that the findings are informative and also brings forth new hypotheses that can be examined in the future.

Conclusions

The frequency of Covid-19 fatalities rose considerably from age group of 30-39 years, but there were a higher number of fatalities in younger patients than in international studies. Diabetes and cardiovascular disorders were most prevalent co-morbidities, although lower than reported in previous studies. Fever, cough, and dyspnoea were common symptoms among the patients infected with Covid-19, however fever and cough were not common among those who eventually died cases compared those who recovered.

Declaration

Acknowledgment. We would like to thank all personnel of Mashhad University of Medical Sciences for their supports. Also, we would like to thank Mashhad University of Medical Sciences for supporting this study with grant number of 981800.

Funding. This work was supported by Mashhad University of Medical Sciences (grant number of 981800).

Ethics approval. This study was approved by the Ethics Committee of the Mashhad University of Medical Science (Ethics code: IR.MUMS.REC.1398.308).

Availability of data and materials. All data will be available upon request by permission of the corresponding author and Research Ethics Committee of Mashhad University of Medical Sciences.

Competing interests. The authors declare that they have no competing interests.

Authors' contributions. BH, RB designed the study design. All authors contributed in data gathering and interpretation of the results. LG, MAR, BH wrote the first draft of the manuscript that was edited by RB. All authors read, commented and approved the final manuscript.

Code availability. Not applicable.

References

1. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. The New England journal of medicine. 2020.
2. Gu X, Cao B, Wang J. Full spectrum of COVID-19 severity still being depicted – Authors' reply. The Lancet. 2020.
3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020.
4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet.
5. Liangsheng Zhang F-mSFCZL. Origin and evolution of the 2019 novel coronavirus. Clinical Infectious Diseases. 2020.
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
7. Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The Lancet. 2020;0(0).

8. Coronavirus disease 2019 (COVID-19) situation report - 51. World Health Organisation; 2020. URL: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10.

9. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020, Vol 12, Page 372. 2020;12(4):372-.

10. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. New England Journal of Medicine. 2020:NEJMoa2005412-NEJMoa.

11. Mahase E. China coronavirus: what do we know so far? BMJ (Clinical research ed). 2020;368:m308.

12. de la Cueva-Alique I, Munoz-Moreno L, de la Torre-Rubio E, Bajo AM, Gude L, Cuenca T, et al. Water soluble, optically active monofunctional Pd(ii) and Pt(ii) compounds: promising adhesive and antimigratory effects on human prostate PC-3 cancer cells. Dalton transactions (Cambridge, England : 2003). 2019;48(38):14279-93.

13. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine. 2020.

14. Liangsheng Zhang F-mSFCZL. Origin and evolution of the 2019 novel coronavirus - Supplementary data. Clinical Infectious Diseases. 2020.

15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.

16. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020:10.1001/jama.2020.1585.

17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.

18. Chen K, Liao QL, Ma ZW, Jin Y, Hua M, Bi J, et al. Association of soil arsenic and nickel exposure with cancer mortality rates, a town-scale ecological study in Suzhou, China. Environmental science and pollution research international. 2015;22(7):5395-404.

19. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine. 2020.

20. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020.

21. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020.

22. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. The New England journal of medicine. 2020.

23. 2017 Iranian Statistical Center 2020 [Available from: https://www.amar.org.ir.

24. Bergquist R, Rinaldi L. Covid-19: Pandemonium in our time. Geospatial health. 2020;15(1).

25. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.

26. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama. 2020.

27. Lippi G, Mattiuzzi C, Sanchis-Gomar F, Henry BM. Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China. Journal of medical virology. 2020.

28. WHO. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) 2020 [cited 2020 March 20]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.

29. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020.

30. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. European journal of nuclear medicine and molecular imaging. 2020;47(5):1275-80.

31. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020.

32. Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou J-J, et al. Isolation and characterization of 2019-nCoV-like coronavirus from Malayan pangolins. BioRxiv. 2020.

33. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.

34. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Archives of academic emergency medicine. 2020;8(1):e35.

35. Xiang YT, Jin Y, Wang Y, Zhang Q, Zhang L, Cheung T. Tribute to health workers in China: A group of respectable population during the outbreak of the COVID-19. International journal of biological sciences. 2020;16(10):1739-40.

36. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.